🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07010341
Recruiting Observational

Quantitative Intra-operative Assessment of Parathyroid Perfusion Using Indocyanine Green (ICG) Fluorescence Imaging

NCT07010341 · tracked via the Priya Life Science China tracker
Sponsor
Fujian Medical University
Phase
Observational
Started
2025-05-01
Last updated
2025-07-15

Condition(s) studied

Thyroid Surgery

Investigational drug(s) / intervention(s)

ntra-operative Indocyanine Green (ICG) Fluorescence Quantification

ntra-operative Indocyanine Green (ICG) Fluorescence Quantification: After a single intravenous bolus of indocyanine green (25 µg/kg), a near-infrared sensor records raw fluorescence intensity from the superior parathyroid gland and the ipsilateral common carotid artery at 60-120 seconds. No images are stored; only peak intensity values are logged to calculate the perfusion ratio R = PTG / CCA. The measurement is observational, adds ≤2 minutes to operative time, and involves no therapeutic intent.

Study summary

This single-center, prospective, three-phase observational cohort quantifies the relationship between indocyanine green (ICG) fluorescence and early parathyroid function. Adult patients scheduled for unilateral thyroid lobectomy with autotransplantation of the ipsilateral inferior parathyroid gland are enrolled. After intravenous ICG 25 µg/kg, peak fluorescence of the superior parathyroid gland and the common carotid artery (CCA) is recorded at 60-120 seconds to calculate the ratio R = PTG/CCA. Serum parathyroid hormone (PTH) is measured 30 minutes post-operatively. A derivation cohort (\~120 patients) generates R-based thresholds for in-situ preservation versus autotransplantation, which are prospectively validated in an independent cohort (60 patients) together with decision-curve analysis of clinical net benefit.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * Scheduled for unilateral thyroid lobectomy plus central (VI-level) lymph-node dissection. * Intra-operative findings consistent with: * Complete identification and in-situ preservation of the ipsilateral superior parathyroid gland; * Complete identification and autotransplantation of the ipsilateral inferior parathyroid gland. * Serum 25-hydroxy-vitamin D ≥ 30 ng/mL at baseline; patients below this level may be enrolled after standardized vitamin-D and calcium supplementation with re-test confirming ≥ 30 ng/mL. * Surgery and all postoperative follow-up performed at the study center. * Able and willing to provide written informed consent. Exclusion Criteria: * Prior surgery on the thyroid or parathyroid glands. * Severe hepatic or renal impairment, or other serious metabolic bone disease. * Pregnancy or lactation. * Known hypersensitivity to indocyanine green or iodine-containing compounds. * Inability or unwillingness to comply with postoperative visits and blood testing.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Fujian Medical University Union Hospital Fuzhou Fujian Not Yet Recruiting
Fujian Medical University Union Hospital Fuzhou Fujian Recruiting

More Fujian Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07010341 on ClinicalTrials.gov ↗ ← All trials in China